Opus Genetics announces departure of Chief Scientific Officer
Opus Genetics, Inc. reports the departure of Dr. Ashwath Jayagopal as Chief Scientific and Development Officer, effective October 19, 2026.
Wrap Technologies Appoints Edward Delatorre to Board
Wrap Technologies, Inc. expands its Board of Directors by appointing Edward Delatorre, increasing the board size to seven members.
Wynn Resorts to Invest MOP1.365 Billion in Macau Fund
Wynn Resorts Ltd. announces a MOP1.365 billion investment in a Macau government fund, enhancing its operational commitments and industry position.
Neogen Corporation Amends Incentive Plan Following Approval
Neogen Corporation's shareholders approve an amended incentive plan, allowing for a wider range of equity-based awards to boost employee engagement.
Oruka Therapeutics reports positive Phase 2b trial results
Oruka Therapeutics announces encouraging results from its Phase 2b trial of ORKA-001 for psoriasis, paving the way for Phase 3 trials in 2027.
Phathom Pharmaceuticals Responds to FDA Docket on VOQUEZNA
Phathom Pharmaceuticals reacts to FDA's public docket on VOQUEZNA's exclusivity, amid ongoing litigation with BDR Pharmaceuticals.
Eikon Therapeutics presents clinical data at oncology congress
Eikon Therapeutics shares promising clinical data from its PARP1 and WRN helicase programs at the European Society for Medical Oncology Congress.
Federal Home Loan Bank of Boston Elects Four New Directors
Federal Home Loan Bank of Boston announces election of four new directors effective January 1, 2027, alongside updated compensation policies.